All Topics
All Topics
Technology
Technology
Design
Design
Programming
Programming
Science
Science
News
News
Gaming
Gaming
Entertainment
Entertainment
Business
Business
Finance
Finance
Sports
Sports
Health
Health
Food
Food
Travel
Travel
Art
Art
Music
Music
Books
Books
Education
Education
Politics
Politics
Personal
Personal
Bluesky
Twitter
No algorithm. No AI slop. No ads. Just RSS. Pro-human. Indie writers. Real journalism. Open web. Chronological. Hand toasted.

How AI Will Transform Biopharma: The Sequence of Change Matters

By

Benjamine Liu

1h ago· 33 min readenInsight

Summary

Ben Liu, CEO of Formation Bio, argues that AI will transform the pharmaceutical industry unevenly and sequentially. Some parts of drug discovery and development are becoming software-like—faster, cheaper, and iterative—while others remain constrained by the physical world, such as patient recruitment, dosing, and long clinical trial timelines. The article explores how the sequence in which these frontiers move determines where value concentrates and where it erodes in the biopharma landscape.

Source

bskyHow AI Will Transform Biopharma: The Sequence of Change Mattersa16z.news

Key quotes

· 4 pulled
AI will transform pharma, but not evenly and not all at once.
Some parts of drug discovery and development are already software-like: faster, cheaper, iterative, driven by model improvements.
Others stay bound by the physical world, such as recruiting patients, dosing them, and waiting years for an endpoint to read out.
The sequence in which these frontiers move determines where value concentrates and where it erodes.
Snippet from the RSS feed
How AI will transform biopharma—and why the sequence of change matters

You might also wanna read